Biocompatibility Studies of Gadolinium Complexes with Iminodiacetic Acid Derivatives

Markowicz-Piasecka, Magdalena; Skupień, Agata; Mikiciuk-Olasik, Elżbieta; Sikora, Joanna

doi:10.1007/s12011-018-1496-6

Cited by 10 publications

(9 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The design and targeted use of different chelating agents which form complexes of variable physicochemical properties appear to affect the bodily distribution of metal radiotracers and are increasingly applied for the diagnosis of different diseases and tracking their progress. Similar targeted chelator metal complexes have been identified for the theranostic application of radiotracer metals in cancer, inflammation and other diseases [29,30].…”

Section: Examples Of the Clinical Applications Of Chelator Metal Compmentioning

confidence: 79%

“…A major area of the application of chelators in medicine is the diagnostic and theranostic fields (Table 1) [29,30]. The design and targeted use of different chelating agents which form complexes of variable physicochemical properties appear to affect the bodily distribution of metal radiotracers and are increasingly applied for the diagnosis of different diseases and tracking their progress.…”

Section: Examples Of the Clinical Applications Of Chelator Metal Compmentioning

confidence: 99%

“…There are major challenges ahead in relation to the new applications of chelators, chelating drugs and their metal complexes in medicine. In addition to biomedical research developments, the continuation of basic chemical research in the design of new chelators and the characterization of their physicochemical and other properties including those of their metal complexes are essential for increasing their targeting potential and therapeutic and/or diagnostic or theranostic application in medicine [1,[29][30][31].…”

Section: Examples Of the Clinical Applications Of Chelator Metal Compmentioning

confidence: 99%

See 2 more Smart Citations

Advances on Chelation and Chelator Metal Complexes in Medicine

Kontoghiorghes¹

2020

IJMS

View full text Add to dashboard Cite

show abstract

Section: Examples Of the Clinical Applications Of Chelator Metal Compmentioning

confidence: 79%

Section: Examples Of the Clinical Applications Of Chelator Metal Compmentioning

confidence: 99%

Section: Examples Of the Clinical Applications Of Chelator Metal Compmentioning

confidence: 99%

See 1 more Smart Citation

Advances on Chelation and Chelator Metal Complexes in Medicine

Kontoghiorghes¹

2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Another major, rapidly expanding area of the application of maltol and other chelators in medicine is in the diagnostic and theranostic fields [ 28 ]. The design and targeted use of different chelating agents, which form metal complexes of variable physicochemical properties, appear to affect the bodily distribution of specific metal radiotracers and are increasingly applied for the diagnosis, as well as progress tracking of different diseases [ 28 , 212 , 213 ]. Similar targeted chelator metal complexes have been identified for the theranostic application of radiotracer metals in inflammation, cancer, and other diseases [ 28 , 212 , 213 ].…”

Section: Potential Applications Of Maltol and Maltol Metal Complexes In Medicinementioning

confidence: 99%

New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications

Kontoghiorghes¹,

Kolnagou²,

Demetriou³

et al. 2021

IJMS

View full text Add to dashboard Cite

The trimaltol iron complex (International Non-proprietary Name: ferric maltol) was originally designed, synthesised, and screened in vitro and in vivo in 1980–1981 by Kontoghiorghes G.J. following his discovery of the novel alpha-ketohydroxyheteroaromatic (KHP) class of iron chelators (1978–1981), which were intended for clinical use, including the treatment of iron deficiency anaemia (IDA). Iron deficiency anaemia is a global health problem affecting about one-third of the world’s population. Many (and different) ferrous and ferric iron complex formulations are widely available and sold worldwide over the counter for the treatment of IDA. Almost all such complexes suffer from instability in the acidic environment of the stomach and competition from other dietary molecules or drugs. Natural and synthetic lipophilic KHP chelators, including maltol, have been shown in in vitro and in vivo studies to form stable iron complexes, to transfer iron across cell membranes, and to increase iron absorption in animals. Trimaltol iron, sold as Feraccru or Accrufer, was recently approved for clinical use in IDA patients in many countries, including the USA and in EU countries, and was shown to be effective and safe, with a better therapeutic index in comparison to other iron formulations. Similar properties of increased iron absorption were also shown by lipophilic iron complexes of 8-hydroxyquinoline, tropolone, 2-hydroxy-4-methoxypyridine-1-oxide, and related analogues. The interactions of the KHP iron complexes with natural chelators, drugs, metal ions, proteins, and other molecules appear to affect the pharmacological and metabolic effects of both iron and the KHP chelators. A new era in the treatment of IDA and other possible clinical applications, such as theranostic and anticancer formulations and metal radiotracers in diagnostic medicine, are envisaged from the introduction of maltol, KHP, and similar lipophilic chelators.

show abstract

“…Lancelot (2016) has discussed the details of the pharmacokinetic profiles of gadolinium‐based contrast agents and points to correlations between thermodynamic stability, clearance rates and Gd ion release with respect to overall biological safety characteristics. Markowicz‐Piasecka et al (2019) have addressed the overall biocompatibility characteristics of gadolinium complexes and shown some effects on cell viability, for example endothelial cells. The reference to ‘scleroderma‐like disease mentioned above is also disturbing.…”

Section: The Triad Of Biocompatibility Device Functionality and Biolmentioning

confidence: 99%

Assessing the triad of biocompatibility, medical device functionality and biological safety

Williams

2020

Med Devices & Sens

View full text Add to dashboard Cite

Biomaterials, defined as 'materials designed to take a form that can direct, through interactions with living systems, the course of any therapeutic or diagnostic procedure' (Zhang & Williams, 2019), are used in an increasing number of medical applications (Williams, 2014a). From both engineering and regulatory perspectives, the 'form' that the biomaterials take is usually referred to as a 'device'; the interaction with living systems may occur in vivo or ex vivo. The devices have functions that range from mechanical (joint replacements, heart valves), optical (intra-ocular lenses) and electrical (cardiac pacemakers, deep brain stimulators) to those of complex systems that may incorporate the delivery of molecules to the body (prolonged release of drugs) or involve diagnostic character (imaging contrast agents, continuous glucose measurement).Of all the required properties of the biomaterials and devices, two are of profound importance. These are biocompatibility and functionality. Biocompatibility, defined as 'the ability of a material to perform with an appropriate host response in a specific application', (Zhang & Williams, 2019) encompasses all types of interaction that can occur between the material / device and the host. These interactions can be considered negatively in the sense that they may inhibit the appropriate host response, for example being responsible for blood clots forming within intravascular devices, or positively if they promote superior host responses, for example enhanced bonding with bone in orthopaedic devices. The full spectrum of potential mechanisms of biocompatibility has not yet been identified, but much progress has been made in recent years (Williams 2008;Williams 2017a;Villanueva-Flores et al. 2020). It is difficult to itemize the required functionality characteristics of medical devices since they vary from one applications to another,

show abstract

Biocompatibility Studies of Gadolinium Complexes with Iminodiacetic Acid Derivatives

Cited by 10 publications

References 25 publications

Advances on Chelation and Chelator Metal Complexes in Medicine

Advances on Chelation and Chelator Metal Complexes in Medicine

New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications

Assessing the triad of biocompatibility, medical device functionality and biological safety

Contact Info

Product

Resources

About